Combioxin SA, a clinical-stage biotechnology company, is happy to announce that it has moved its offices to the Biopôle in Epalinges, Switzerland. Combioxin is committed to the development of disruptive treatments for severe infections. The company is a recipient of the Swiss FIT SEED program and is a spin-off of LASCCO SA, a company that propels academic discovery-stage inventions into life science ventures.